CN102014907A - 外周作用阿片拮抗剂的口服给药 - Google Patents

外周作用阿片拮抗剂的口服给药 Download PDF

Info

Publication number
CN102014907A
CN102014907A CN2009801164862A CN200980116486A CN102014907A CN 102014907 A CN102014907 A CN 102014907A CN 2009801164862 A CN2009801164862 A CN 2009801164862A CN 200980116486 A CN200980116486 A CN 200980116486A CN 102014907 A CN102014907 A CN 102014907A
Authority
CN
China
Prior art keywords
opioid
opioid antagonist
therapeutically effective
peripherally
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801164862A
Other languages
English (en)
Chinese (zh)
Inventor
凯文·J·布罗德贝克
艾伦·R·库格勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of CN102014907A publication Critical patent/CN102014907A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2009801164862A 2008-05-07 2009-05-07 外周作用阿片拮抗剂的口服给药 Pending CN102014907A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12686808P 2008-05-07 2008-05-07
US61/126,868 2008-05-07
PCT/US2009/002856 WO2009137086A1 (en) 2008-05-07 2009-05-07 Oral administration of peripherally-acting opioid antagonists

Publications (1)

Publication Number Publication Date
CN102014907A true CN102014907A (zh) 2011-04-13

Family

ID=40888194

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801164862A Pending CN102014907A (zh) 2008-05-07 2009-05-07 外周作用阿片拮抗剂的口服给药

Country Status (15)

Country Link
US (1) US20110160239A1 (enExample)
EP (1) EP2300009A1 (enExample)
JP (1) JP2011519930A (enExample)
KR (1) KR20110004425A (enExample)
CN (1) CN102014907A (enExample)
AU (1) AU2009244805B2 (enExample)
BR (1) BRPI0912219A2 (enExample)
CA (1) CA2723685C (enExample)
EA (1) EA201001643A1 (enExample)
IL (1) IL208794A0 (enExample)
MX (1) MX2010011727A (enExample)
MY (1) MY156913A (enExample)
NZ (1) NZ589733A (enExample)
WO (1) WO2009137086A1 (enExample)
ZA (1) ZA201007531B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104254332A (zh) * 2011-12-19 2014-12-31 萨利克斯药品有限公司 使用甲基纳曲酮口服组合物治疗和预防阿片类诱发型便秘的方法
CN104546791A (zh) * 2013-10-16 2015-04-29 辽宁亿灵科创生物医药科技有限公司 一种阿片受体拮抗剂的固体制剂及其制备方法
WO2017092638A1 (zh) * 2015-12-01 2017-06-08 江苏恒瑞医药股份有限公司 阿片样受体拮抗剂类衍生物、其制备方法及其在医药上的应用

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2368553T1 (sl) 2003-04-08 2015-05-29 Progenics Pharmaceuticals, Inc. Farmacevtske formulacije, vsebujoče metilnatrekson
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
US8524276B2 (en) * 2010-03-11 2013-09-03 Wyeth, Llc Oral formulations and lipophilic salts of methylnaltrexone
MX2013003587A (es) 2010-09-30 2013-05-31 Nektar Therapeutics Conjugados de naloxol-polietilenglicol cristalinos.
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CN106470999B (zh) 2014-04-28 2018-11-13 奥佛麦德公司 叔丁啡二聚体及其在治疗肠胃失调中的应用
AU2015290098B2 (en) 2014-07-17 2018-11-01 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
CN107033154B (zh) 2016-02-02 2020-02-04 上海瀚迈生物医药科技有限公司 阿片受体拮抗剂缀合物及其应用
CN109134479A (zh) * 2017-06-27 2019-01-04 石家庄蒎格医药科技有限公司 结晶聚乙二醇纳洛酮草酸盐及制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050136031A1 (en) * 2003-12-16 2005-06-23 Bentley Michael D. Chemically modified small molecules

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451806B2 (en) * 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
CZ299726B6 (cs) * 1999-11-01 2008-11-05 Lécivo pro lécení zácpy a syndromu dráždivého tracníku
US7056500B2 (en) * 2001-10-18 2006-06-06 Nektar Therapeutics Al, Corporation Polymer conjugates of opioid antagonists
US20060182692A1 (en) * 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
CN101466381B (zh) * 2006-04-21 2012-11-14 尼克塔治疗公司 吗啡酮的立体选择性还原
CN101534827A (zh) * 2006-11-07 2009-09-16 尼克塔治疗亚拉巴马公司 阿片样物质激动剂和阿片样物质拮抗剂的剂型和联合给药

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050136031A1 (en) * 2003-12-16 2005-06-23 Bentley Michael D. Chemically modified small molecules

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ELDON ET AL: "NKTR-118 (Oral PEG-Naloxol), a PEGylated Derivative of Naloxone: Demonstration of Selective Peripheral Opioid Antagonism After Oral Administration in Preclinical Models", 《THE AMERICAN ACADEMY OF PAIN MANAGEMENT 18TH ANNUAL CLINICAL MEETING》 *
NEUMANN TA ,ET AL: "Clinical investigation of NKTR-118 as a selective oral peripheral opioid antagonist", 《THE AMERICAN ACADEMY OF PAIN MANAGEMENT 18TH ANNUAL CLINICAL MEETING》 *
PAULSON D ET AL: "Alvimopan,a novel ,peripherally-acting,mu-opioid receptor antagonist for the management of opioid-induced bowel dysfunction(OBD):Positive results from a phase III randomized,placebo-controlled,21-day trial", 《THE JOURNAL OF PAIN》 *
WEBSTER L ET AL: "A randomized,double-blind,placebo-controlled,multicenter phase IIb study to evaluate the efficacy and safety of multiple alvimopan dosage regimens for the treatment of gastrointestinal adverse events(GIAEs) associated with opioid use in subjects", 《THE JOURNAL OF PAIN》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104254332A (zh) * 2011-12-19 2014-12-31 萨利克斯药品有限公司 使用甲基纳曲酮口服组合物治疗和预防阿片类诱发型便秘的方法
CN104546791A (zh) * 2013-10-16 2015-04-29 辽宁亿灵科创生物医药科技有限公司 一种阿片受体拮抗剂的固体制剂及其制备方法
WO2017092638A1 (zh) * 2015-12-01 2017-06-08 江苏恒瑞医药股份有限公司 阿片样受体拮抗剂类衍生物、其制备方法及其在医药上的应用
CN107406456A (zh) * 2015-12-01 2017-11-28 江苏恒瑞医药股份有限公司 阿片样受体拮抗剂类衍生物、其制备方法及其在医药上的应用
CN107406456B (zh) * 2015-12-01 2019-08-30 江苏恒瑞医药股份有限公司 阿片样受体拮抗剂类衍生物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
IL208794A0 (en) 2010-12-30
AU2009244805A1 (en) 2009-11-12
KR20110004425A (ko) 2011-01-13
EP2300009A1 (en) 2011-03-30
JP2011519930A (ja) 2011-07-14
NZ589733A (en) 2012-07-27
ZA201007531B (en) 2012-03-28
BRPI0912219A2 (pt) 2015-10-06
CA2723685A1 (en) 2009-11-12
MX2010011727A (es) 2010-11-30
WO2009137086A1 (en) 2009-11-12
CA2723685C (en) 2016-09-27
EA201001643A1 (ru) 2011-06-30
AU2009244805B2 (en) 2013-01-10
US20110160239A1 (en) 2011-06-30
MY156913A (en) 2016-04-15

Similar Documents

Publication Publication Date Title
CA2723685C (en) Oral administration of peripherally-acting opioid antagonists
US20190388430A1 (en) Opioid and antiemetic combination compositions for increased pain relief
KR101545874B1 (ko) 난용성 약물의 전달을 위한 입상 조성물
US20030191147A1 (en) Opioid antagonist compositions and dosage forms
JP2004515455A (ja) オピオイドアンタゴニスト組成物および投薬形態
US20160106680A1 (en) Abuse Deterrent Immediate Release Formulation
WO2003039561A1 (en) Pharmaceutical composition
WO2012056402A2 (en) Formulations and methods for attenuating respiratory depression induced by opioid overdose
AU2001259458B2 (en) Opioid antagonist compositions and dosage forms
AU2014233453A1 (en) Compositions with a rheological modifier to reduce dissolution variability
US20180228797A1 (en) Pharmaceutical compositions
AU2001259458A1 (en) Opioid antagonist compositions and dosage forms
EP2968178B1 (en) Pharmaceuticals comprising a ph-dependent component and ph-raising agent
JP5797655B2 (ja) 消化管障害のためのオピオイド受容体アンタゴニストの使用
EP4473961A1 (en) Oral solid pharmaceutical formulation comprising methadone/levomethadone and optionally naloxone
US20250345324A1 (en) Combination formulations of naloxone and atipamezole
US20210085672A1 (en) Oral tablet formulations
AU2019201397A1 (en) Formulations and methods for attenuating respiratory depression induced by opioid overdose
US20160256453A1 (en) Opioid receptor antagonist for use in treating patients with severe constipation induced by high opiate dosage regimen

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110413